Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 5 (2008), Issue 4 (April)

1. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
   Haematologica, 93(4): 533-42. [Abstract] [Full-text]
2. Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor.
   Cancer Sci, 99(4): 799-804. [Abstract] [Full-text]
3. Homoharringtonine for the treatment of chronic myelogenous leukemia.
   Expert Opin Pharmacother, 9(6): 1029-37. [Abstract] [Full-text]
4. Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.
   Pediatr Blood Cancer, 50(5): 1060-2. [Abstract] [Full-text]
5. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
   Int J Cancer, 122(11): 2621-7. [Abstract] [Full-text]
6. Constitutive Overexpression of P-glycoprotein, Rather than Breast Cancer Resistance Protein or Organic Cation Transporter 1, Contributes to Acquisition of Imatinib-Resistance in K562 Cells.
   Pharm Res, 25(4): 827-35. [Abstract] [Full-text]
7. Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia.
   Pathol Biol (Paris). [Abstract] [Full-text]
8. Initial testing of dasatinib by the pediatric preclinical testing program.
   Pediatr Blood Cancer, 50(6): 1198-206. [Abstract] [Full-text]
9. Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets.
   Curr Opin Oncol, 20(3): 270-4. [Abstract] [Full-text]
10. ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells.
    Pharmacol Res, 57(3): 214-22. [Abstract] [Full-text]
11. Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit.
    J Cancer Res Clin Oncol, 134(6): 697-704. [Abstract] [Full-text]
12. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
    Blood, 111(8): 4355-64. [Abstract] [Full-text]
13. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.
    Blood, 111(8): 4022-8. [Abstract] [Full-text]
14. Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia.
    Leuk Lymphoma, 49(4): 643-7. [Abstract] [Full-text]
15. Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia.
    Leuk Lymphoma, 49(4): 639-42. [Abstract] [Full-text]
16. Immunotherapeutic approaches in chronic myelogenous leukemia.
    Leuk Lymphoma, 49(4): 629-34. [Abstract] [Full-text]
17. New therapeutic approaches and prognostic factors in chronic myeloid leukemia.
    Leuk Lymphoma, 49(4): 625-8. [Abstract] [Full-text]
18. Signal interception-based therapies--a double-edged sword in Bcr/abl-induced malignancies?
    Leuk Lymphoma, 49(4): 620-4. [Abstract] [Full-text]
19. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
    Leuk Lymphoma, 49(4): 615-9. [Abstract] [Full-text]
20. BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts.
    Leuk Lymphoma, 49(4): 610-4. [Abstract] [Full-text]
21. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Cancer Chemother Pharmacol. [Abstract] [Full-text]
22. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.
    Proc Natl Acad Sci U S A, 105(14): 5507-12. [Abstract] [Full-text]
23. Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations.
    Cancer, 112(8): 1744-53. [Abstract] [Full-text]
24. Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer.
    Future Oncol, 4(2): 211-7. [Abstract] [Full-text]
25. Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy.
    Cancer Genet Cytogenet, 182(2): 95-102. [Abstract] [Full-text]
26. BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism.
    Leukemia, 22(4): 791-9. [Abstract] [Full-text]
27. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors.
    Leukemia, 22(4): 748-55. [Abstract] [Full-text]
28. Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL.
    Int J Cancer, 122(12): 2744-52. [Abstract] [Full-text]
29. KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors.
    Clin Cancer Res, 14(8): 2285-94. [Abstract] [Full-text]
30. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.
    Mol Cancer Ther, 7(4): 944-51. [Abstract] [Full-text]
31. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations.
    Cancer Res, 68(8): 2576-80. [Abstract] [Full-text]
32. Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy.
    Leuk Res. [Abstract] [Full-text]
33. Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial.
    Anticancer Drugs, 19(5): 527-33. [Abstract] [Full-text]
34. Gastrointestinal stromal tumor.
    Surg Oncol, 17(2): 129-38. [Abstract] [Full-text]
35. Restoration of energy metabolism in leukemic mice treated by a siddha drug--Semecarpus anacardium Linn. nut milk extract.
    Chem Biol Interact, 173(1): 43-58. [Abstract] [Full-text]
36. STI571/doxorubicin concentration-dependent switch for diverse caspase actions in CML cell line K562.
    Biochem Pharmacol, 75(9): 1761-73. [Abstract] [Full-text]
37. The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction.
    World J Surg Oncol, 6: 37. [Abstract] [Full-text]
38. Twin pregnancy in a patient of chronic myeloid leukemia on imatinib therapy.
    Leuk Res. [Abstract] [Full-text]
39. Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors.
    Eur J Surg Oncol, 34(5): 563-8. [Abstract] [Full-text]
40. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
    Leuk Res, 32(7): 1022-5. [Abstract] [Full-text]
41. Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma: a report from the Pediatric Brain Tumor Consortium (PBTC).
    Eur J Nucl Med Mol Imaging. [Abstract] [Full-text]
42. The discovery and application of gene fusions in prostate cancer.
    BJU Int. [Abstract] [Full-text]
43. Imatinib mesilate for the treatment of gastrointestinal stromal tumour.
    Expert Opin Pharmacother, 9(7): 1211-22. [Abstract] [Full-text]
44. Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?
    Acta Haematol, 119(2): 104-7. [Abstract] [Full-text]
45. Getting to the stem of chronic myeloid leukaemia.
    Nat Rev Cancer, 8(5): 341-50. [Abstract] [Full-text]
46. A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer.
    Pancreas, 36(4): 341-5. [Abstract] [Full-text]
47. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement.
    J Clin Pathol, 61(5): 677-80. [Abstract] [Full-text]
48. Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2.
    J Cell Biochem, 104(2): 680-91. [Abstract] [Full-text]
49. The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: The example of sunitinib for gastrointestinal stromal tumour.
    Eur J Cancer, 44(7): 972-7. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.